Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
IUPHAR review-Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
OWL833, an orally active nonpeptide GLP-1 receptor agonist, improves glucose tolerance by increasing insulin secretion and reduces food intake of cynomolgus monkeys
This indicates that dose adjustments for these drugs are not typically needed
GLP-1 and Appetite Regulation: The Role of Brain-Gut Signaling GLP-1 is not only produced in the gut but also acts in the brains hypothalamus, where it influences hunger and satiety signals
Avoid sticking to the same spot to lower the risk of tissue damage or bumps
Pricing is for one 2mL vial but concentrations vary (20mg-60mg vials)
US$ 24.15
US$ 27.20
US$ 24.30
US$ 26.05
US$ 24.42
